Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia

The designation may make ALTO-101 eligible for more frequent meetings with the FDA, as well as possible accelerated approval and priority review, provided relevant criteria are me ...
The Manila Times

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for ...

I-Mab Biopharma: I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for pa ...
Fierce Pharma

Amgen, AZ's Tezspire gains 2nd FDA nod, upping the ante in its battle with Dupixent

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...

When healing turns harmful: Adrenal support cells tied to cancer origin

A new study from Karolinska Institutet, published in npj Precision Oncology, shows that support cells in the adrenal gland ...